Lymph node-based prognostics: Limitations with individualized cancer treatment

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 3, 2006, Pages 298-304

  Kendal, Wayne S ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Breast cancer; Evidence based medicine; Gastric cancer; Rectal cancer; SEER

Indexed keywords

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER REGISTRY; CANCER SURVIVAL; DIAGNOSTIC APPROACH ROUTE; GENETIC HETEROGENEITY; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIVIDUALIZATION; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECTUM CANCER; RISK FACTOR; STATISTICAL ANALYSIS; STOMACH CANCER; BREAST TUMOR; EVALUATION; FEMALE; MALE; PATHOLOGY; PATIENT CARE PLANNING; PREDICTION AND FORECASTING; RECTUM TUMOR; STATISTICS; STOMACH TUMOR;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; PATIENT CARE PLANNING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECTAL NEOPLASMS; RISK FACTORS; SEER PROGRAM; STOMACH NEOPLASMS;

EID: 33745003418     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000214929.01001.16     Document Type: Article

References (39)

1. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52:1551-1557.
2. Tang R, Wang JY, Chen JS, et al. Survival impact of lymph node metastasis in TNM stage III carcinoma of the colon and rectum. J Am Coll Surg. 1995;180:705-712.
3. Kodera Y, Yamamura Y, Shimizu Y, et al. The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. J Am Coll Surg. 1998;187:597-603.
4. Merkel DE, Osborne CK. Prognostic factors in breast cancer. Hematol Oncol Clin North Am. 1989;3:641-652.
5. Aapro MS. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001. Oncologist. 2001;6:376-385.
6. Natsugoe S, Matsumoto M, Okumura H, et al. Prognostic factors in patients with submucosal esophageal cancer. J Gastrointest Surg. 2004;8:631-635.
7. Chee JJ, Ho TH, Tay EH, Low JJ, Yam KL. Endometrioid adenocarcinoma of the uterus: surgico-pathological correlations and role of pelvic lymphadenectomy. Ann Acad Med Singapore. 2003;32:670-675.
8. Al Ghamdi AM, Jewett MA. Stage I nonseminomatous germ cell tumors: the case for management by risk stratification. Can J Urol. 2005;12(Suppl 1):62-65.
9. Denschlag D, Gabriel B, Mueller-Lantzsch C, et al. Evaluation of patients after extraperitoneal lymph node dissection for cervical cancer. Gynecol Oncol. 2005;96:658-664.
10. Ulmer C, Bembenek A, Gretschel S, et al. Refined staging by sentinel lymph node biopsy to individualize therapy in anal cancer. Ann Surg Oncol. 2004;11(Suppl):259S-262S.
11. Takeda N, Sakuragi N, Takeda M, et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand. 2002;81:1144-1151.
12. Burczynski ME, Oestreicher JL, Cahilly MJ, et al. Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. Curr Mol Med. 2005;5:83-102.
13. Pusztai L, Rouzier R, Wagner P, Symmans WF. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Drug Resist Updat. 2004;7:325-331.
14. Tchabo NE, Liel MS, Kohn EC. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer. Am J Pharmacogenomics. 2005;5:141-148.
15. Maruyama K, Gunven P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg. 1989;210:596-602.
16. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol. 1990;16:127-133.
17. Goldstein NS. Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. Am J Surg Pathol. 2002;26:179-189.
18. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163:49-56.
19. Weiss L. Random and nonrandom processes in metastasis, and metastatic inefficiency. Invasion Metastasis. 1983;3:193-207.
20. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER* Stat Database: Incidence: SEER 9 Regs Public-Use, Nov 2003 Sub (1973-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission, 2004.
21. Iyer RV, Hanlon A, Fowble B, et al. Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined. Int J Radiation Oncol Biol Phys. 2000;47:1177-1183.
22. Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer. 2002;94:2862-2866.
23. Ichikura T, Ogawa T, Chochi K, Kawabata T, Sugasawa H, Mochizuki H. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma. World J Surg. 2003;27:330-333.
24. Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst. 2005;97:219-225.
25. Mantel N. Ranking procedures for arbitrarily restricted observations. Biometrics. 1967;23:65-78.
26. Woodward M. Epidemiology: Study Design and Data Analysis. New York: Champman & Hall/CRC, 1999.
27. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39:499-503.
28. Schulgen G, Olschewski M, Krane V, Wanner C, Ruf G, Schumacher M. Sample sizes for clinical trials with time-to-event endpoints and competing risks. Contemp Clin Trials. 2005;26:386-396.
29. Konstadoulakis MM, Messaris E, Zografos G, Ricaniadis N, Androulakis G, Karakousis C. Common prognostic factors for stage III melanoma patients and for stage I and II melanoma patients with recurrence to their regional lymph nodes. Melanoma Res. 2002;12:357-364.
30. Raspagliesi F, Ditto A, Paladini D, et al. Prognostic indicators in melanoma of the vulva. Ann Surg Oncol. 2000;7:738-742.
31. Daneshmand S, Quek ML, Stein JP, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004;172(Pt 1):2252-2255.
32. Cheng X, Cai S, Li Z, Tang M, Xue M, Zang R. The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery. World J Surg Oncol. 2004;2:47.
33. Sasaki R, Takahashi M, Funato O, et al. Prognostic significance of lymph node involvement in middle and distal bile duct cancer. Surgery. 2001;129:677-683.
34. Kunisaki C, Shimada H, Akiyama H, Nomura M, Matsuda G, Ono H. Prognostic factors in esophageal cancer. Hepatogastroenterology. 2004;51:736-740.
35. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002;95:1434-1443.
36. Yasunaga M, Yamasaki F, Tokunaga O, Iwasaka T. Endometrial carcinomas with lymph node involvement: novel histopathologic factors for predicting prognosis. Int J Gynecol Pathol. 2003;22:341-346.
37. Tomik J, Skladzien J, Modrzejewski M. Evaluation of cervical lymph node metastasis of 1400 patients with cancer of the larynx. Auris Nasus Larynx. 2001;28:233-240.
38. Vinh-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res. 2004;6:R680-R688.
39. Bast RC Jr, Hortobagyi GN. Individualized care for patients with cancer: a work in progress. N Engl J Med. 2004;351:2865-2867.